VRCDF (Verici Dx) Ending Cash Position: $3.34 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Verici Dx Ending Cash Position?

Verici Dx VRCDF -60.53% Ending Cash Position is $3.34 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

Verici Dx's Ending Cash Position for the quarter that ended in Dec. 2025 was $3.34 Mil.

Verici Dx's quarterly Ending Cash Position declined from Dec. 2024 ($4.06 Mil) to Jun. 2025 ($0.47 Mil) but then increased from Jun. 2025 ($0.47 Mil) to Dec. 2025 ($3.34 Mil).

Verici Dx's annual Ending Cash Position increased from Dec. 2023 ($2.65 Mil) to Dec. 2024 ($4.06 Mil) but then declined from Dec. 2024 ($4.06 Mil) to Dec. 2025 ($3.34 Mil).

Verici Dx Ending Cash Position Related Terms

Verici Dx Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Verici Dx's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Verici Dx Ending Cash Position Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 10.34 9.81 2.65 4.06 3.34

Verici Dx Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 2.65 7.02 4.06 0.47 3.34

Verici Dx Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Verici Dx's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=4.061+-0.718
=3.34

Verici Dx's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.467+2.876
=3.34

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $3.34 Mil mean?
Verici Dx (VRCDF) has a Ending Cash Position of $3.34 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Verici Dx and its competitors.
Is Verici Dx's Ending Cash Position too high?
Verici Dx's current Ending Cash Position is $3.34 Mil.
How does Verici Dx's Ending Cash Position compare to TMO and DHR?
Verici Dx's Ending Cash Position of $3.34 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Diagnostics & Research company?
A good Ending Cash Position depends on the Medical Diagnostics & Research industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Verici Dx and its competitors. Verici Dx's current Ending Cash Position is $3.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (VRCDF) has a current Ending Cash Position of $3.34 Mil. The current Ending Cash Position is $3.34 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Verici Dx (VRCDF), the current Ending Cash Position is $3.34 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Verici Dx Business Description

Other Exchanges VRCI:UK63V:Germany
Address 19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.